AIM
NBIX icon

Acrospire Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Acrospire Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,200
Closed -$46K – 2396
2016
Q4 		$46K Buy
1,200
+1,000
+500% +$45.3K 0.02% 1449
2016
Q3 		$10K Sell
200
-200
-50% -$9.96K 0.01% 1701
2016
Q2 		$18K Buy
+400
New +$18.4K 0.01% 1565

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acrospire Investment Management's NBIX Position: Q1 2017 in Review

Acrospire Investment Management sold out of Neurocrine Biosciences (NBIX) in Q1 2017, closing a stake of 1,200 shares — an estimated $46K sold.

Acrospire Investment Management first reported a position in NBIX in Q2 2016 and held it in 3 quarters. The position peaked at $46K in Q4 2016. 218 funds tracked by Wall St. Rank hold NBIX as of Q1 2017.

  • Acrospire Investment Management reported no remaining Neurocrine Biosciences position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 1,200 Neurocrine Biosciences shares in Q1 2017, an estimated $46K.
  • Acrospire Investment Management first reported a position in Neurocrine Biosciences in Q2 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Neurocrine Biosciences position peaked at $46K in Q4 2016.
  • 218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.